Press

1. IntelliDose Launches IntelliScribe March 2, 2010
2. IntrinsiQ Sharpens Cancer Treatment Analysis February 10, 2010
3. Dayton Physicians Commits to Clinical Excellence by Partnering with IntelliDose February 2, 2010
4. IntelliDose Exhibiting at Fifth Annual Community Oncology Conference February 5–6, 2010
5. New York cancer care center uses automation to handle coding, reimbursement January 29, 2010
6. Tarceva Reprieve? FDA Delay Could Mean Little Either Way January 25, 2010
7. WWMR Vice President Invited to Speak at PBIRG Fall Biotech Workshop December 7, 2009
8. Panel Advises on Clinical Pathways: What, Why, and How November, 2009
9. IntrinsiQ Expands Executive Team November 3, 2009
10. IntelliDose Exhibiting at North Carolina Oncology Management Society 2009 Fall Conference November 18 to 20, 2009
11. Opportunity reconsidered: maintenance therapy in oncology October, 2009
12. IntrinsiQ Study: Oncologists Overlook Maintenance Therapy Option – More Often than They Realize September 15, 2009
13. Industry Thought Leaders: A Discussion with Jeff Forringer, President of IntrinsiQ, LLC August 2009
14. Are CPOEs worth the investment? August 2009
15. Information Technology: Tracking the Evolution of Oncology Drug Prescribing August 2009
16. Rich Gray, General Manager of IntelliDose, to Speak at ACCC 26th National Oncology Economics Conference September 22 to 25, 2009
17. IntelliDose Exhibiting at eClinicalWorks 2009 National Users Conference September 12 to 15, 2009
18. Jeff Forringer, President of IntrinsiQ, to Speak at the Magellan/ICORE 6th Annual Oncology Summit September 11, 2009
19. IntelliDose Exhibiting at GE Centricity User Group Fall Conference August 28 and 29, 2009
20. How Much Should Cancer Drugs Cost: Landmark Cornell University Study Sheds New Light on Old Assumptions August 4, 2009
21. IntrinsiQ Sponsors Cancer Center Business Summit October 8-9, 2009
22. The First Step to a Paperless Practice July 1, 2009
23. On the Move – Spotlight on Jeff Forringer June 19, 2009
24. Specialized chemotherapies increase market share, cost of care June 2009
25. IntrinsiQ Acquires Market Research Firm WWMR June 9, 2009
26. IntrinsiQ Appoints New Executive Team May 12, 2009
27. IntrinsiQ's IntelliDose May 2009
28. The real cost of treating off-label and off-guidelines March 2009
29. NewsMakers March 2009
30. Small mistakes, huge consequences; Onc-specific software improves safety February 2009
31. Safe Handling; The Right Drug, Right Dose, Right Patient January/February 2009
32. Automated Oncology February 2009
33. Still Using Paper and Pen? January 2009
34. OnCare Hawaii Selects IntelliDose for Oncology Patient Safety and Practice Efficiency January 6, 2009
35. Safe Handling December 2008
36. Market Opportunity in Lung Cancer December 2008
37. Cancer Center of South Florida Selects IntelliDose for All-Electronic Practice November 3, 2008
38. IntrinsiQ Launches IntelliDose 3.8 October 27, 2008
39. Technology: Can Oncology EMRs Improve Quality? September 2008
40. IntrinsiQ Builds Out Its Oncology-Products Market Analytics September 2008
41. IntrinsiQ Wins 3 Top Honors from Inc. Magazine September 9, 2008
42. New Reporting from IntrinsiQ Measures Impact of Key Events on Oncology Drug Usage September 2, 2008
43. High Drug Costs a Factor in Cancer Care August 28, 2008
44. Pharmawire analysis: Cyclacel's seliciclib comes under physician scrutiny August 2008
45. DSS Licenses IntelliDose to Standardize VA Oncology Practices August 18, 2008
46. Buried Treasure June 23, 2008
47. Data from the Doctor April 15, 2008
48. IntrinsiQ LLC - Dose of Success March 7, 2008
49. IntelliCost Provides Cost of Therapy Insight for Sizing New Market Opportunities February 13, 2008
50. Software application aims to eliminate human error in chemotherapy dosing January 11, 2008
51. Oncologists Nationwide Choose IntelliDose for Clinical Safety and Efficiency November 28, 2007
52. IntrinsiQ Expands Oncology’s Gold-Standard for Patient Data Collection September 25, 2007
53. IntelliDose to Participate in ASCO EHR Symposium July 19, 2007
54. GE Healthcare and IntrinsiQ Announce Collaboration to Link Clinical Oncology Information within Patient Electronic Medical Records May 31, 2007
55. IntelliDose® Unveils IntelliCharge — Automated Encounter Charge Capture Improves Control and Billing of Costly Chemotherapy Drugs May 31, 2007
56. PRA International and IntrinsiQ Research Enter Exclusive Agreement for Oncology Patient Treatment Data March 19, 2007
57. Pulse and IntrinsiQ Sign Strategic Agreement January 16, 2007
58. IMS, IntrinsiQ Research Establish Strategic Alliance to Deliver Global, Clinically Rich Oncology Market Intelligence August 2, 2006
59. Accel-KKR Acquires Majority Stake in IntrinsiQ June 20, 2006

FOR IMMEDIATE RELEASE

IntrinsiQ Expands Oncology’s Gold-Standard for Patient Data Collection

IntelliTraQ – New Web-Based Longitudinal Patient Tracking Tool

Waltham, Mass. (Sept. 25, 2007) — IntrinsiQ, LLC, the leading provider of U.S. oncology market data and business analytics to pharmaceutical, biotechnology and financial companies today launched IntelliTraQ®, the industry’s most comprehensive Web-based survey tool for cancer drug usage.

IntelliTraQ expands the reach and flexibility of IntrinsiQ’s flagship product, IntelliDose®, the largest data tracking resource for oncologists nationwide. IntrinsiQ currently gathers data regarding the treatment of more than 18,500 patients per month.

IntrinsiQ is the only source for automated longitudinal data on trends in cancer drug usage and is relied on by 27 of the 30 largest oncology companies.

More Analysis and Insight

The accessibility of this Web-based data collection expands the potential sample size by hundreds of additional practitioners. IntelliTraQ’s flexibility and analytics gives pharmaceutical marketers new insight into emerging trends and patterns of usage. It delivers:

• The ability to change data collection parameters, including modifying elements and customizing reports
• New profile analysis to drill down into subsets of data by geographic region, patient sub-population and other significant groups
• Deeper understanding into why something is occurring, with more qualitative data in addition to the existing quantitative data

IntelliDose answers the critical question: “What is happening?” IntelliTraQ brings insight to the next level, by seeking to answer the follow-on question: “Why is this happening?”

“IntrinsiQ is the gold standard in U.S. oncology tracking today,” said Jeff Forringer, general manager of the IntrinsiQ Pharmaceutical Data Division. “We provide historic perspective and trend analysis on more than 7 million drug administrations – no one else comes close. The convenience and flexibility of IntelliTraQ will make it even easier for oncologists to contribute their experiences.”

For pharmaceutical marketers, the larger potential sample size of U.S. oncologists has immediate business value:

• Robust sample sizes in the U.S. market that provide actionable information in the later lines of therapy and smaller tumors, when critical decisions need to be made
• Holistic and complete patient treatment understanding positions Phase IV clinical and economic outcomes to support formulary decisions by payors
• Regional and other demographic snapshots provide more sophisticated and targeted illustrations, and are extremely helpful in shaping sales reps’ compensation plans
• Quantifiable and linked views between physician perception and actual physician behavior in order to refine marketing messages that get heard and acted upon

New Reality: More Competition

The oncology market grows more sophisticated each year, as pharmaceutical companies vie to stay ahead of increased competition and more rigorous approval cycles.

IntrinsiQ is the national leader in medical oncology care software and the only source for automated longitudinal data on trends in cancer drug usage. Its up-to-theminute record of more than 128,000 drug administrations provided monthly to 18,500 individual patients is unmatched.

“For pharmaceutical companies to stay ahead, they need data that’s broad, deep and accurate,” said Brent Clough, president and CEO of IntrinsiQ. “We provide insight on more than 1.5 million drug administrations each year. And we help turn that data into insights that drive business strategy – and best practices for oncologists.”

About IntrinsiQ

IntrinsiQ, LLC is the premier source for US oncology data and analysis. Each month, IntrinsiQ’s market leading software application, IntelliDose®, captures the treatment decisions and details from more than 550 unique physicians, for more than 18,500 unique patients, and regarding more than 128,000 drug administrations. The IntrinsiQ database is unrivaled in accuracy, detail and timeliness of information about the medical oncology care process. This database is the foundation of products and services that uniquely address the business information needs of pharmaceutical product managers, market researchers and financial analysts. For more information, please visit www.intrinsiq.com.

Contact

Brent Clough
IntrinsiQ, LLC
(781) 647-1144

© 2010 IntrinsiQ, LLC